dihydroxyphenylalanine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 57 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Persistent dyskinesias in the absence of or with only minimal amounts of dopaminergic medication have been reported after dopamine cell implantation for Parkinson's disease." | 2.70 | Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. ( Breeze, R; Dhawan, V; Eidelberg, D; Fahn, S; Feigin, A; Freed, C; Fukuda, M; Greene, P; Ma, Y; Shi, Q, 2002) |
| "With respect to Parkinson's disease PET and later SPECT allowed the number of dopaminergic neurons to be assessed in vivo." | 2.46 | [Nuclear medicine imaging in patients with Parkinson's syndrome: an update]. ( Schwarz, J, 2010) |
| "Two subjects presented with action tremor around age 10-12 years and developed tremor-dominant parkinsonism with prominent neuropsychiatric features later in their 20s." | 1.72 | WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia. ( Berutti, R; Bonifati, V; Boumeester, V; Brunet, T; Gdovinova, Z; Han, V; Havrankova, P; Houlden, H; Jech, R; Kaiyrzhanov, R; Kuipers, DJS; Kulcsarova, K; Lackova, A; Mandemakers, W; Orec, L; Ostrozovicova, M; Pavelekova, P; Plecko, B; Rektorova, I; Rizig, M; Skorvanek, M; Steinfeld, R; Tijssen, MAJ; Wagner, M; Winkelmann, J; Zech, M, 2022) |
| "28 subjects had idiopathic Parkinson's disease (14 male, 14 female; age at scan 61 +- 11,5), 13 atypical Parkinsonian disease (7 male, 6 females; age at scan: 69,6 +- 6,4) and 17 were controls (6 male, 11 female; age at scan 65,3 +-8,6)." | 1.56 | Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders. ( Chaves, LT; De Jong, BM; Dierckx, RAJO; Doorduin, J; Kremer, BPH; Leenders, KL; Stormezand, GN; Vállez García, D, 2020) |
| " The loaded gel was administered in different doses and dosing regimens to Parkinsonian rats, and the catalepsy score and striatal DA levels were assessed." | 1.42 | Potential efficacy of dopamine loaded-PVP/PAA nanogel in experimental models of Parkinsonism: possible disease modifying activity. ( Abd El-Rehim, HA; El-Ghazaly, MA; Rashed, ER, 2015) |
| "Levodopa and placebo treated animals exhibited a similar number of surviving dopaminergic cells in the SN." | 1.40 | Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway. ( Arbizu, J; Collantes, M; DiCaudo, C; Luquin, MR; Marcilla, I; Ordóñez, C; Peñuelas, I; Riverol, M, 2014) |
| " The long-term use of LD is limited by the development of L-DOPA-induced dyskinesias and dystonia." | 1.39 | The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia. ( Aley-Medina, P; Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; García-Ruiz, R; Gutiérrez-Valdez, AL; Montiel-Flores, E; Reynoso-Erazo, L; Sánchez-Betancourt, J; Torres-Esquivel, C; Tron-Alvarez, R, 2013) |
| " Study of pharmacokinetic parameters (AUC, C(max), and T(max)) revealed a greater and more extended release of ropinirole from nanoemulsion gel compared to that from a conventional gel (RPG) and oral marketed tablet (Ropitor)." | 1.38 | Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. ( Ahmad, FJ; Azeem, A; Iqbal, Z; Khar, RK; Negi, LM; Talegaonkar, S, 2012) |
| "The third part of the unified Parkinson's disease rating scale (UPDRS) was used to evaluate the development of PD symptom before and 1 hour after taking the medicine." | 1.35 | [Acute dopaminergic responsiveness test in diagnosis of Parkinson's disease and Parkinsonian disorders]. ( Feng, T; Li, W; Lin, JX; Wang, YJ; Xu, XT, 2008) |
| "This tremor was refractory to gabapentin and dramatically responded to Levodopa administration." | 1.34 | Dopa-responsive pseudo-orthostatic tremor in parkinsonism. ( Antonini, A; Barone, P; Bonanni, L; Onofrj, M; Thomas, A, 2007) |
| "Parkinsonism was induced using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine." | 1.32 | Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. ( Bezard, E; Di Monte, DA; Hsu, A; Langston, JW; Quik, M; Sokoloff, P; Togasaki, DM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (24.56) | 18.7374 |
| 1990's | 1 (1.75) | 18.2507 |
| 2000's | 22 (38.60) | 29.6817 |
| 2010's | 11 (19.30) | 24.3611 |
| 2020's | 9 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Eisenberg, DP | 1 |
| Lopez, G | 1 |
| Gregory, MD | 1 |
| Berman, KF | 1 |
| Sidransky, E | 1 |
| Skorvanek, M | 1 |
| Rektorova, I | 1 |
| Mandemakers, W | 1 |
| Wagner, M | 1 |
| Steinfeld, R | 1 |
| Orec, L | 1 |
| Han, V | 1 |
| Pavelekova, P | 1 |
| Lackova, A | 1 |
| Kulcsarova, K | 1 |
| Ostrozovicova, M | 1 |
| Gdovinova, Z | 1 |
| Plecko, B | 1 |
| Brunet, T | 1 |
| Berutti, R | 1 |
| Kuipers, DJS | 1 |
| Boumeester, V | 1 |
| Havrankova, P | 1 |
| Tijssen, MAJ | 1 |
| Kaiyrzhanov, R | 1 |
| Rizig, M | 1 |
| Houlden, H | 1 |
| Winkelmann, J | 1 |
| Bonifati, V | 1 |
| Zech, M | 1 |
| Jech, R | 1 |
| Goldfarb, L | 1 |
| Iep, A | 1 |
| Chawki, MB | 1 |
| Nguyen, L | 1 |
| Lun, F | 1 |
| Carpentier, AAN | 1 |
| de Recondo, A | 1 |
| Blin, J | 1 |
| Bourdinaud, V | 1 |
| Morin, L | 1 |
| Andriatsiferana, H | 1 |
| Ferreira, A | 1 |
| Deschiens, AM | 1 |
| Brulon, V | 1 |
| Comtat, C | 1 |
| Lebon, V | 1 |
| Besson, FL | 1 |
| Lim, SY | 1 |
| Tan, AH | 1 |
| Tay, YW | 1 |
| Stormezand, GN | 1 |
| Chaves, LT | 1 |
| Vállez García, D | 1 |
| Doorduin, J | 1 |
| De Jong, BM | 1 |
| Leenders, KL | 1 |
| Kremer, BPH | 1 |
| Dierckx, RAJO | 1 |
| da Silva Schmitt, G | 1 |
| Martinez, ARM | 1 |
| da Graça, FF | 1 |
| de Lima, FD | 1 |
| Bonadia, LC | 1 |
| Amorim, BJ | 1 |
| Nucci, A | 1 |
| França, MC | 1 |
| Sood, A | 1 |
| Shukla, J | 1 |
| Shree, R | 1 |
| Vatsa, R | 1 |
| Modi, M | 1 |
| Mittal, BR | 1 |
| Speck, AE | 1 |
| Aguiar, AS | 1 |
| Ferreira, SG | 1 |
| Silva, HB | 1 |
| Tomé, ÂR | 1 |
| Agostinho, P | 1 |
| Cunha, RA | 1 |
| Prediger, RD | 1 |
| Guo, Q | 1 |
| Wang, B | 1 |
| Wang, X | 1 |
| Smith, WW | 1 |
| Zhu, Y | 1 |
| Liu, Z | 1 |
| Criswell, SR | 1 |
| Nielsen, SS | 1 |
| Warden, M | 1 |
| Perlmutter, JS | 1 |
| Moerlein, SM | 1 |
| Flores, HP | 1 |
| Huang, J | 1 |
| Sheppard, L | 1 |
| Seixas, N | 1 |
| Checkoway, H | 1 |
| Racette, BA | 1 |
| Wu, J | 1 |
| Zhao, YM | 1 |
| Deng, ZK | 1 |
| Riverol, M | 1 |
| Ordóñez, C | 1 |
| Collantes, M | 1 |
| DiCaudo, C | 1 |
| Peñuelas, I | 1 |
| Arbizu, J | 1 |
| Marcilla, I | 1 |
| Luquin, MR | 1 |
| Gutiérrez-Valdez, AL | 1 |
| García-Ruiz, R | 1 |
| Anaya-Martínez, V | 1 |
| Torres-Esquivel, C | 1 |
| Espinosa-Villanueva, J | 1 |
| Reynoso-Erazo, L | 1 |
| Tron-Alvarez, R | 1 |
| Aley-Medina, P | 1 |
| Sánchez-Betancourt, J | 1 |
| Montiel-Flores, E | 1 |
| Avila-Costa, MR | 1 |
| Rashed, ER | 1 |
| Abd El-Rehim, HA | 1 |
| El-Ghazaly, MA | 1 |
| Darcourt, J | 1 |
| Schiazza, A | 1 |
| Sapin, N | 1 |
| Dufour, M | 1 |
| Ouvrier, MJ | 1 |
| Benisvy, D | 1 |
| Fontana, X | 1 |
| Koulibaly, PM | 1 |
| Goldstein, DS | 1 |
| Holmes, C | 1 |
| Sharabi, Y | 1 |
| Wu, T | 1 |
| Li, W | 1 |
| Feng, T | 1 |
| Wang, YJ | 1 |
| Lin, JX | 1 |
| Xu, XT | 1 |
| Lipton, J | 1 |
| Rivkin, MJ | 1 |
| Björklund, T | 1 |
| Hall, H | 1 |
| Breysse, N | 1 |
| Soneson, C | 1 |
| Carlsson, T | 1 |
| Mandel, RJ | 1 |
| Carta, M | 1 |
| Kirik, D | 1 |
| Schwarz, J | 1 |
| Azeem, A | 1 |
| Talegaonkar, S | 1 |
| Negi, LM | 1 |
| Ahmad, FJ | 1 |
| Khar, RK | 1 |
| Iqbal, Z | 1 |
| Joutsa, J | 1 |
| Martikainen, K | 1 |
| Niemelä, S | 1 |
| Johansson, J | 1 |
| Forsback, S | 1 |
| Rinne, JO | 1 |
| Kaasinen, V | 1 |
| Walker, MD | 1 |
| Dinelle, K | 1 |
| Kornelsen, R | 1 |
| McCormick, S | 1 |
| Mah, C | 1 |
| Holden, JE | 2 |
| Farrer, MJ | 1 |
| Stoessl, AJ | 2 |
| Sossi, V | 1 |
| Kock, N | 1 |
| Müller, B | 1 |
| Vieregge, P | 1 |
| Pramstaller, PP | 1 |
| Marder, K | 1 |
| Abbruzzese, G | 1 |
| Martinelli, P | 1 |
| Lang, AE | 1 |
| Jacobs, H | 1 |
| Hagenah, J | 1 |
| Harris, J | 1 |
| Meija-Santana, H | 1 |
| Fahn, S | 2 |
| Hedrich, K | 2 |
| Kann, M | 1 |
| Gehlken, U | 1 |
| Culjkovic, B | 1 |
| Schwinger, E | 1 |
| Wszolek, ZK | 1 |
| Zühlke, C | 1 |
| Klein, C | 2 |
| Pal, PK | 1 |
| Leung, J | 1 |
| Samii, A | 1 |
| Lieberman, A | 1 |
| Nausieda, PA | 1 |
| Calne, DB | 1 |
| Breakefield, XO | 1 |
| Ma, Y | 1 |
| Feigin, A | 1 |
| Dhawan, V | 1 |
| Fukuda, M | 1 |
| Shi, Q | 1 |
| Greene, P | 1 |
| Breeze, R | 1 |
| Freed, C | 1 |
| Eidelberg, D | 1 |
| Huang, WS | 1 |
| Ma, KH | 1 |
| Chou, YH | 1 |
| Chen, CY | 1 |
| Liu, RS | 1 |
| Liu, JC | 1 |
| BIRKMAYER, W | 2 |
| HORNYKIEWICZ, O | 2 |
| GERSTENBRAND, F | 1 |
| PATEISKY, K | 1 |
| PROSENZ, P | 1 |
| MCGEER, PL | 1 |
| ZELDOWICZ, LR | 1 |
| UMBACH, W | 1 |
| BAUMANN, D | 1 |
| TRAVENED, I | 1 |
| TRAVENEC, I | 1 |
| SCHULTE, W | 1 |
| HIRSCHMANN, J | 2 |
| MAYER, K | 2 |
| DESCHAEPDRYVER, A | 1 |
| SOURKES, TL | 1 |
| PIVNICKI, D | 1 |
| BROWN, WT | 1 |
| WISEMAN-DISTLER, H | 1 |
| MURPHY, GF | 1 |
| SANKOFF, I | 1 |
| SAINTCYR, S | 1 |
| DIEMATH, HE | 1 |
| HEPPNER, F | 1 |
| ENGE, S | 1 |
| LECHNER, H | 1 |
| LAVERTY, R | 1 |
| SHARMAN, DF | 1 |
| Fontan, A | 1 |
| Rojo, A | 1 |
| Sanchez Pernaute, R | 1 |
| Hernández, I | 1 |
| López, I | 1 |
| Castilla, C | 1 |
| Sanchez Albisua, J | 1 |
| Perez Higueras, A | 1 |
| Al-Rashid, I | 1 |
| Rabano, A | 1 |
| Gonzalo, I | 1 |
| Angeles Mena, M | 1 |
| Cools, A | 1 |
| Eshuis, S | 1 |
| Maguire, P | 1 |
| Pruim, J | 1 |
| Leenders, K | 1 |
| Garcia de Yebenes, J | 1 |
| Kishima, H | 1 |
| Poyot, T | 1 |
| Bloch, J | 2 |
| Dauguet, J | 1 |
| Condé, F | 1 |
| Dollé, F | 1 |
| Hinnen, F | 1 |
| Pralong, W | 1 |
| Palfi, S | 2 |
| Déglon, N | 2 |
| Aebischer, P | 2 |
| Hantraye, P | 2 |
| Hsu, A | 1 |
| Togasaki, DM | 2 |
| Bezard, E | 1 |
| Sokoloff, P | 1 |
| Langston, JW | 2 |
| Di Monte, DA | 1 |
| Quik, M | 1 |
| Doudet, DJ | 1 |
| Cornfeldt, ML | 1 |
| Honey, CR | 1 |
| Schweikert, AW | 1 |
| Allen, RC | 1 |
| Honer, M | 1 |
| Hengerer, B | 1 |
| Blagoev, M | 1 |
| Hintermann, S | 1 |
| Waldmeier, P | 1 |
| Schubiger, PA | 1 |
| Ametamey, SM | 1 |
| Thomas, A | 1 |
| Bonanni, L | 1 |
| Antonini, A | 1 |
| Barone, P | 1 |
| Onofrj, M | 1 |
| Seibyl, JP | 1 |
| Chen, W | 1 |
| Silverman, DH | 1 |
| Abe, Y | 1 |
| Kachi, T | 1 |
| Kato, T | 1 |
| Ito, K | 1 |
| Yanagisawa, N | 1 |
| Sobue, G | 1 |
| Kordower, JH | 1 |
| Emborg, ME | 1 |
| Ma, SY | 1 |
| Chu, Y | 1 |
| Leventhal, L | 1 |
| McBride, J | 1 |
| Chen, EY | 1 |
| Roitberg, BZ | 1 |
| Brown, WD | 1 |
| Pyzalski, R | 1 |
| Taylor, MD | 1 |
| Carvey, P | 1 |
| Ling, Z | 1 |
| Trono, D | 1 |
| Chekhonin, VP | 1 |
| Baklaushev, VP | 1 |
| Kogan, BM | 1 |
| Savchenko, EA | 1 |
| Lebedev, SV | 1 |
| Man'kovskaya, IV | 1 |
| Filatova, TS | 1 |
| Yusupova, IU | 1 |
| Dmitrieva, TB | 1 |
| Cumming, P | 2 |
| Danielsen, EH | 1 |
| Vafaee, M | 1 |
| Falborg, L | 1 |
| Steffensen, E | 1 |
| Sørensen, JC | 1 |
| Gillings, N | 1 |
| Bender, D | 1 |
| Marthi, K | 1 |
| Andersen, F | 1 |
| Munk, O | 1 |
| Smith, D | 1 |
| Møller, A | 1 |
| Gjedde, A | 1 |
| Munk, OL | 1 |
| Doudet, D | 1 |
| Yee, RE | 1 |
| Irwin, I | 1 |
| Milonas, C | 1 |
| Stout, DB | 1 |
| Huang, SC | 1 |
| Shoghi-Jadid, K | 1 |
| Satyamurthy, N | 1 |
| Delanney, LE | 1 |
| Farahani, KF | 1 |
| Delfani, K | 1 |
| Janson, AM | 1 |
| Phelps, ME | 1 |
| Barrio, JR | 1 |
| Thobois, S | 1 |
| Guillouet, S | 1 |
| Broussolle, E | 1 |
| Yoshimura, M | 1 |
| Yamamoto, T | 1 |
| Iso-o, N | 1 |
| Imafuku, I | 1 |
| Momose, T | 1 |
| Shirouzu, I | 1 |
| Kwak, S | 1 |
| Kanazawa, I | 1 |
| Ishihara, K | 1 |
| Nonaka, A | 1 |
| Fukui, T | 1 |
| Kawamura, M | 1 |
| Shiota, J | 1 |
| Nakano, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Embryonic Dopamine Cell Implants for Parkinson's Disease: A Double-Blind Study[NCT00038116] | Phase 3 | 40 participants (Actual) | Interventional | 1995-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for dihydroxyphenylalanine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
18F-FDOPA PET for the diagnosis of parkinsonian syndromes.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Humans; Image Processing, Computer-Assisted; Par | 2014 |
[Nuclear medicine imaging in patients with Parkinson's syndrome: an update].
Topics: Animals; Brain; Dihydroxyphenylalanine; Disease Progression; Dopamine; Energy Metabolism; Fluorodeox | 2010 |
[PSYCHOPHARMACA: OBSERVATIONS AND INTERPRETATIONS].
Topics: Amphetamine; Amphetamines; Caudate Nucleus; Central Nervous System Stimulants; Chlorpromazine; Dihyd | 1964 |
3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors.
Topics: Adrenal Gland Neoplasms; Amino Acids; Brain Neoplasms; Caudate Nucleus; Dihydroxyphenylalanine; Fluo | 2007 |
Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Topics: Aging; Animals; Antiparkinson Agents; Basal Ganglia; Brain Tissue Transplantation; Cell Transplantat | 2001 |
1 trial available for dihydroxyphenylalanine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Dyskinesia after fetal cell transplantation for parkinsonism: a PET study.
Topics: Adult; Brain; Caudate Nucleus; Cohort Studies; Dihydroxyphenylalanine; Double-Blind Method; Dyskines | 2002 |
51 other studies available for dihydroxyphenylalanine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Comparison of Transcranial Sonography and [
Topics: Dihydroxyphenylalanine; Dopamine; Glucosylceramidase; Humans; Mutation; Parkinsonian Disorders; Posi | 2022 |
WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia.
Topics: Ataxia; Dihydroxyphenylalanine; Humans; Mutation; Myoclonus; Parkinsonian Disorders; Phenotype; Spin | 2022 |
Head-to-Head Comparison Between Rabbit Sign and EANM/SNMMI Criteria for the 18F-DOPA Visual Assessment of Parkinsonian Syndromes in PET/MRI: A Multiple Expert-Based and Blinded Controlled Study.
Topics: Animals; Dihydroxyphenylalanine; Humans; Magnetic Resonance Imaging; Parkinsonian Disorders; Positro | 2023 |
Deep brain stimulation in Dopa-Responsive Parkinsonism - Look out for red flags: Expert commentary.
Topics: Deep Brain Stimulation; Dihydroxyphenylalanine; Humans; Parkinson Disease; Parkinsonian Disorders | 2023 |
Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders.
Topics: Aged; Caudate Nucleus; Corpus Striatum; Diagnosis, Differential; Dihydroxyphenylalanine; Female; Hum | 2020 |
Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
Topics: Atrophy; Dihydroxyphenylalanine; Homozygote; Humans; Multiple System Atrophy; Parkinsonian Disorders | 2020 |
Comparative Performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT Imaging in Patients With Parkinson's Disease, Parkinson-Plus Syndrome, and Essential Tremor.
Topics: Dihydroxyphenylalanine; Essential Tremor; Female; Humans; Male; Middle Aged; Organotechnetium Compou | 2021 |
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine | 2021 |
Activation of Nrf2 in Astrocytes Suppressed PD-Like Phenotypes via Antioxidant and Autophagy Pathways in Rat and Drosophila Models.
Topics: Adenine; Animals; Animals, Genetically Modified; Antioxidants; Antiparkinson Agents; Astrocytes; Aut | 2021 |
[
Topics: Adult; Corpus Striatum; Cross-Sectional Studies; Dihydroxyphenylalanine; Female; Humans; Magnetic Re | 2018 |
Neuroprotective action and mechanistic evaluation of protodioscin against rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain; Cell Line, Tumor; Cognition; Dihydroxyphenylalanine; Diosgenin; Di | 2018 |
Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dihydroxypheny | 2014 |
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Administration, Oral; Animals; Cannabinoid Receptor Antagonists; Corpus Striatum; Dihydroxyphenylala | 2013 |
Potential efficacy of dopamine loaded-PVP/PAA nanogel in experimental models of Parkinsonism: possible disease modifying activity.
Topics: Acrylic Resins; Animals; Catalepsy; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Male; | 2015 |
Survival in synucleinopathies: A prospective cohort study.
Topics: Aged; alpha-Synuclein; Brain; Cerebellar Diseases; Cohort Studies; Dihydroxyphenylalanine; Female; F | 2015 |
[Acute dopaminergic responsiveness test in diagnosis of Parkinson's disease and Parkinsonian disorders].
Topics: Adult; Aged; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Middle | 2008 |
16p11.2-related paroxysmal kinesigenic dyskinesia and dopa-responsive parkinsonism in a child.
Topics: Adolescent; Chromosomes, Human, Pair 16; Dihydroxyphenylalanine; Dyskinesias; Humans; Male; Middle A | 2009 |
Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats.
Topics: Animals; Biopterins; Corpus Striatum; Dependovirus; Dihydroxyphenylalanine; Dopamine; Female; Geneti | 2009 |
Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Antiparkinson Agents; Biological Availabil | 2012 |
Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders.
Topics: Aged; Compulsive Behavior; Dihydroxyphenylalanine; Disruptive, Impulse Control, and Conduct Disorder | 2012 |
In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Fluorine Radiois | 2013 |
Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism.
Topics: Age of Onset; Ataxins; Dihydroxyphenylalanine; Dopamine Agents; Drug Resistance; Humans; Nerve Tissu | 2002 |
[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism.
Topics: Adolescent; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; DNA Mutational Analysis; Domin | 2002 |
99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Macaca; Metabolic Clearance Rate; Models, Animal; | 2003 |
[The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis].
Topics: Dihydroxyphenylalanine; Humans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Parkinsonian | 1962 |
[EXPERIENCES WITH L-DOPA IN THE THERAPY OF PARKINSONISM].
Topics: Dihydroxyphenylalanine; Humans; Levodopa; Parkinsonian Disorders | 1963 |
ADMINISTRATION OF DIHYDROXYPHENYLALANINE TO PARKINSONIAN PATIENTS.
Topics: Dihydroxyphenylalanine; Dopamine; Extrapyramidal Tracts; Geriatrics; Humans; Injections, Intravenous | 1964 |
[THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY].
Topics: Brain; Dihydroxyphenylalanine; Levodopa; Neurosurgery; Neurosurgical Procedures; Parkinsonian Disord | 1964 |
[PATHOGENESIS OF THE BASIC SYMPTOMS OF PARKINSONISM DUE TO BIOCHEMICAL CHANGES IN THE SUBCORTICAL AND STEM STRUCTURES OF THE EXTRAPYRAMIDAL SYSTEM].
Topics: Brain; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Extrapyramidal Tracts; Humans; Microsco | 1964 |
[PATHOGENESIS OF THE BASIC SYMPTOMS OF PARKINSONISM DUE TO BIOCHEMICAL CHANGES IN THE SUBCORTICAL AND STEM STRUCTURES OF THE EXTRAPYRAMIDAL SYSTEM].
Topics: Brain; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Extrapyramidal Tracts; Humans; Microsco | 1964 |
[PSYCHIATRIC UNIVERSITY CLINIC AND PSYCHIATRIC STATE HOSPITAL].
Topics: Aging; Brain Diseases; Dihydroxyphenylalanine; Germany; Germany, West; Hospitals, Psychiatric; Hospi | 1964 |
[ON THE CONTROL OF AKINESIA AND OTHER EXTRAPYRAMIDAL MOTOR DISORDERS WITH L-DOPA (L-DIHYDROXYPHENYLALANINE)].
Topics: Chorea; Dihydroxyphenylalanine; Electromyography; Extrapyramidal Tracts; Humans; Levodopa; Monoamine | 1964 |
[NEW MEANS OF CONTROLLING EXTRAPYRAMIDAL MOTOR DISORDERS].
Topics: Central Nervous System Diseases; Dihydroxyphenylalanine; Drug Therapy; Electroencephalography; Extra | 1964 |
A CLINICAL AND METABOLIC STUDY OF DOPA (3, 4-DIHYDROXYPHENYLALANINE) AND METHYLDOPA IN HUNTINGTON'S CHOREA.
Topics: Body Fluids; Chorea; Dihydroxyphenylalanine; Drug Therapy; Electroencephalography; Fluids and Secret | 1965 |
[ELECTROENCEPHALOGRAMS DURING ADMINISTRATION OF L-DOPA BEFORE, IN (DEPTH LEADS AND STIMULATION EFFECTS) AND AFTER STEREOTACTIC BRAIN OPERATIONS IN PARKINSON PATIENTS].
Topics: Brain; Dihydroxyphenylalanine; Electroencephalography; Levodopa; Neurosurgery; Neurosurgical Procedu | 1964 |
MODIFICATION BY DRUGS OF THE METABOLISM OF 3,4-DIHYDROXYPHENYLETHYLAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE BRAIN.
Topics: Animals; Atropine; Behavior, Animal; Brain; Brain Chemistry; Cats; Caudate Nucleus; Cerebral Cortex; | 1965 |
[ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].
Topics: Biomedical Research; Brain; Catecholamines; Dihydroxyphenylalanine; Levodopa; Metabolism; Parkinson | 1964 |
Effects of fibroblast growth factor and glial-derived neurotrophic factor on akinesia, F-DOPA uptake and dopamine cells in parkinsonian primates.
Topics: Animals; Cell Count; Dihydroxyphenylalanine; Dopamine; Fibroblast Growth Factor 2; Fluorine Radioiso | 2002 |
Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons.
Topics: Animals; Capsules; Dihydroxyphenylalanine; Fluorine Radioisotopes; Genetic Therapy; Glial Cell Line- | 2004 |
Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys.
Topics: Animals; Dihydroxyphenylalanine; Disease Models, Animal; Drug Interactions; Dyskinesias; Female; Par | 2004 |
PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease.
Topics: Animals; Binding, Competitive; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Female; Hum | 2004 |
Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Male; Mice; Mice, Inbred C57BL; Neurotra | 2006 |
Dopa-responsive pseudo-orthostatic tremor in parkinsonism.
Topics: Adult; Dihydroxyphenylalanine; Dopamine Agents; Female; Humans; Male; Middle Aged; Parkinsonian Diso | 2007 |
[Diagnostic utility of positron emission tomography for parkinsonism after chronic manganese exposure].
Topics: Diagnosis, Differential; Dihydroxyphenylalanine; Fluorine Radioisotopes; Humans; Male; Manganese Poi | 1999 |
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antigens, CD; Dihydroxyphenylalanine; | 2000 |
Catecholamines and their metabolites in the brain and urine of rats with experimental Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catecholamines; Dihydroxyphenylalanine; Dopamine; Ep | 2000 |
Normalization of markers for dopamine innervation in striatum of MPTP-lesioned miniature pigs with intrastriatal grafts.
Topics: Animals; Antineoplastic Agents; Dihydroxyphenylalanine; Dopamine; Graft Survival; Isoquinolines; Par | 2001 |
Loss of metabolites from monkey striatum during PET with FDOPA.
Topics: Animals; Blood-Brain Barrier; Denervation; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Flu | 2001 |
Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Dise | 2001 |
Hemiparkinsonism associated with a mesencephalic tumor.
Topics: Brain Stem Neoplasms; Carbon Radioisotopes; Caudate Nucleus; Dihydroxyphenylalanine; Dopamine Agents | 2002 |
Lewy body-free nigral degeneration--a case report.
Topics: Aged; Dihydroxyphenylalanine; Fatal Outcome; Female; Humans; Lewy Bodies; Nerve Degeneration; Parkin | 2002 |